Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ASKA: Competition Cuts Sales, Profits
June 2, 2008
- R&D NEWS IN BRIEF
June 2, 2008
- Toyama Chemical: Geninax Lifts Sales 61.7%
June 2, 2008
- OPINION／Leaders Are Readers
June 2, 2008
- Agreement Rate of Over 70% by End of Sept. Acceptable?
June 2, 2008
- CV Market to Level Off in 2008 after Major NHI Price Revision
June 2, 2008
- No Losses due to Sales Prices Lower than Invoice Prices: Hearings Completed with 20 Wholesalers
June 2, 2008
- Daiichi Sankyo Prepares for Next Leap in FY2008
June 2, 2008
- Makers Should Reconsider Invoice Prices as Market Prices Change: Mr Hamada
June 2, 2008
- STOP PRESS
June 2, 2008
- BUSINESS NEWS IN BRIEF
June 2, 2008
- 8 Top Domestic Companies Report Strong Growth in Overseas Sales, Big Increases in R&D Spending
June 2, 2008
- Bungyo Will Spread through Promotion of the Use of Generics: Mr Mitsuhara
June 2, 2008
- Otsuka: Pharma Sales Up 11.1% to \640.2 Bil.
June 2, 2008
- Individual Doctors Should Be Free to Choose Generics or Original Drugs: Dr Fujiwara of JMA
June 2, 2008
- Ono: Opalmon Pushes Up Sales by 3.0%
June 2, 2008
- Daiichi Sankyo to Acquire U3 Pharma of Germany
June 2, 2008
- Will Generics Take Off? (Final)
June 2, 2008
- Kyorin: Sales Up 5.2% Driven by Good Sales of Kipres
June 2, 2008
- Protosera Cooperates with 5 Firms to Search for Biomarkers
June 2, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…